O

Ondine Biomedical Inc
LSE:OBI

Watchlist Manager
Ondine Biomedical Inc
LSE:OBI
Watchlist
Price: 10.25 GBX -8.89%
Market Cap: 53.1m GBX

Ondine Biomedical Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Ondine Biomedical Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
O
Ondine Biomedical Inc
LSE:OBI
Cash from Operating Activities
-CA$15.5m
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Cash from Operating Activities
-$5.8m
CAGR 3-Years
32%
CAGR 5-Years
38%
CAGR 10-Years
3%
Profound Medical Corp
TSX:PRN
Cash from Operating Activities
-$37.5m
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
-22%
Theralase Technologies Inc
XTSX:TLT
Cash from Operating Activities
-CA$2.5m
CAGR 3-Years
22%
CAGR 5-Years
15%
CAGR 10-Years
5%
MedMira Inc
XTSX:MIR
Cash from Operating Activities
-CA$3.1m
CAGR 3-Years
-19%
CAGR 5-Years
-58%
CAGR 10-Years
-2%
Conavi Medical Corp
XTSX:CNVI
Cash from Operating Activities
-$15.3m
CAGR 3-Years
23%
CAGR 5-Years
-9%
CAGR 10-Years
4%
No Stocks Found

Ondine Biomedical Inc
Glance View

Market Cap
53.1m GBX
Industry
Health Care

Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.

OBI Intrinsic Value
10.35 GBX
Undervaluation 1%
Intrinsic Value
Price
O

See Also

What is Ondine Biomedical Inc's Cash from Operating Activities?
Cash from Operating Activities
-15.5m CAD

Based on the financial report for Dec 31, 2024, Ondine Biomedical Inc's Cash from Operating Activities amounts to -15.5m CAD.

What is Ondine Biomedical Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-7%

Over the last year, the Cash from Operating Activities growth was -13%. The average annual Cash from Operating Activities growth rates for Ondine Biomedical Inc have been -7% over the past three years .

Back to Top